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EDITORIAL 

HEPATIC METASTASES FROM COLORECTAL CARCINOMA 

The treatment of metastasis from tumors of the gastro 
intestinal tract is considered by most to be at best, only 
palliative. This may be a rather nihilistic approach. 
Indeed the surgical literature increasingly shows that an 
aggresive attitude towards distant metastasis may be of 
benefit to some patients. 
Colorectal Carcinoma is one of the increasing afflictions 
and is the 2nd commonest cause of death from cancer in 
the Western world. It accounts from 14% of cancer 
deaths in men and 16% of deaths in women. Put into 
perspective one person in five in the United Kingdom 
now dies from cancer and one in eight of these will die 
from tumors of the large bowel. 
To date the best prognostic indicator for survival in 
colorectal disease has been based on the extent and 
spread of the disease. The modified Dukes' classification 
still remains the best prognostic tool when dealing with 
5 year survival. 
Based on this classification, Dukes' A, by definition, is 
early cancer, yet despite this there is only an 85% 
survival at 5 years. The prognosis is obviously worse 
with the Band C category. Greenway concludes that 
30% of patients who undergo curative resection of 
colorectal cancinoma die of metastatic disease in the 
liver. It has also been suggested that dissemination of 
metastasis to extrahepatic sites such as lung and bone is 
frequently by secondary metastasis from deposits that 
have already occured in the liver. 
These findings are therefore sufficient to justify a more 
aggressive policy towards liver metastasis. To date 
chemotherapy and surgery are the possible treatment 
options. However before discussing such options the 
natural history of liver metastosis ought to be considered. 
Solitary or low volume liver mets can be associated with 
prolonged survival even if left untreated (20% 3 year 
survival). Few 5 year survivors have been documented 
by Wagner but none in the extensive series by Hughes et 
al and Schec1e et al. Indeed such dismal results justify an 
aggresi ve treatment policy by the latter and other such as 
Doci and Gennari. 
Liver surgery varies from extensive type of resections 
such as lobectomy or extended lobectomy to non ana­
tomical resection such as metastasectomy, the latter 
morbidity and mortality still remains rather high. Both 
recent Italian and German literature suggest a 10% 
mortality with an additional 13% major complication 
rate. 
Despite extensive liver surgery, the 5 year survival 
remains limited to 10 - 32%. The extent of liver involve­
ment appears to be the most important parameter related 
to survival. No 5-year survivors have been documented 
in patients with more than 50% of liver involvement at 
the time of resection. In contrast a significantly better 
result of 40% 5 year survival was achieved in patients 
with <25% liver involvement. 
Overall 69% of all those resected die of recurrent dis­
ease. Sixty per cent of these show evidence of liver 
deposits either alone or in combination with other 
extrahepatic sites. 
It may be argued that operative risks in patients with 
limited survival may not be justified when othermodalities 
of treatment, such as chemotherapy, are in existence. 
Extensive trials with chemotherapy have been under­
taken with widely varying results. Several clear points 
however emerge. Only 5 Flourouracil appear to be 
beneficial in this disease. This drug appears to be effec­
tive in liver metastasis only when administered 
intrahepatic ally via the hepatic artery. Intravenous ad­
ministration is only of value in stemming the spread of 
extrahepatic disease. 
Considerable morbidity is still a problem associated with 
chemotherapy and at present the long term res u I ts may be 
slightly inferior to surgery. 
The slightly better results of surgery over chemotherapy 
might be negated by the mortality associated with sur­
gery. The overall results for both surgery and chemo­
therapy are not ideal yet. However careful selection and 
treatment of patients with small volume metastasis may 
result in better 5 year survival. 
accounting for up to 1/3 of all liver surgery. This type of ~ 
surgery is not without complications. Whilst some au­
thors report no intraoperative deaths, post operative THE EDITOR 
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